Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Novo Nordisk A/S (NVO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Novo Nordisk ADR's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
123.05 -0.97    -0.78%
- Closed. Currency in USD ( Disclaimer )
After Hours
123.00
-0.05
-0.04%
- Real-time Data
Type:  Equity
Market:  United States
  • Volume: 5,711,241
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 121.29 - 123.77
Novo Nordisk ADR 123.05 -0.97 -0.78%

NVO Balance Sheet

 
Featured here, the Balance Sheet for Novo Nordisk A/S, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2024
31/03
2023
31/12
2023
30/09
2023
30/06
Total Current Assets 116421 139646 142199 137551
Cash and Short Term Investments 9303 30230 47595 36408
Cash - - - -
Cash & Equivalents 6324 14392 30144 21574
Short Term Investments 2979 15838 17451 14834
Total Receivables, Net 71750 75261 61964 70521
Accounts Receivables - Trade, Net 56999 64770 52602 61294
Total Inventory 33600 31811 29534 28020
Prepaid Expenses - - - -
Other Current Assets, Total 1768 2344 3106 2602
Total Assets 298921 314486 300101 280753
Property/Plant/Equipment, Total - Net 98230 90961 81461 75024
Property/Plant/Equipment, Total - Gross - 138583 - -
Accumulated Depreciation, Total - -47622 - -
Goodwill, Net - 4464 - -
Intangibles, Net 59640 60406 55726 50749
Long Term Investments 1651 1663 1471 1479
Note Receivable - Long Term 14751 10491 9362 9227
Other Long Term Assets, Total 2012 1430 430 338
Other Assets, Total -12436 -9352 6941 -9453
Total Current Liabilities 165606 169655 172552 156618
Accounts Payable 13006 25606 20106 17788
Payable/Accrued - - - -
Accrued Expenses - 99427 - -
Notes Payable/Short Term Debt 10164 456 6613 6289
Current Port. of LT Debt/Capital Leases - 6022 - -
Other Current liabilities, Total 142436 38144 145833 132541
Total Liabilities 200010 207925 207110 190280
Total Long Term Debt 16764 20528 19924 19415
Long Term Debt 16764 15976 19924 19415
Capital Lease Obligations - 4552 - -
Deferred Income Tax 9664 10162 7885 7627
Minority Interest - - - -
Other Liabilities, Total -2188 7124 136 331
Total Equity 98911 106561 92991 90473
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 451 451 451 451
Additional Paid-In Capital - - - -
Retained Earnings (Accumulated Deficit) 99050 104839 91735 88118
Treasury Stock - Common -5 -5 -5 -3
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total -585 1276 810 1907
Total Liabilities & Shareholders' Equity 298921 314486 300101 280753
Total Common Shares Outstanding 4457.37 - 4476.9 4490.4
Total Preferred Shares Outstanding - - - -
* In Millions of DKK (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NVO Comments

Write your thoughts about Novo Nordisk A/S
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Serafino Aloe
Serafino Aloe 16 hours ago
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Io oggi carico di brutto
Grumpy Cat
Grumpy Cat Apr 18, 2024 9:38AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this company was doing so well, what happened.
Jackson Nahm
Jackson Nahm Apr 18, 2024 9:38AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Profit taking imo, it’ll go higher
Keith Dunkelbarger
Keith Dunkelbarger Apr 17, 2024 6:27PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A1C down from 9.4 to 6.2 and weight down from 254 to 238 with Ozempic. Lot of flatulence and air freshener.
yeongjin white
yeongjin white Mar 14, 2024 11:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
300 by 2024
roy reyes
roy reyes Feb 05, 2024 8:07PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
gonna dominate the obesity space with Catalent mreger
Karsten Vester
Karsten Vester Feb 01, 2024 4:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
450 by 2030.. Serving 1 mill custumors now and there are 800 mill. U do the math..
D Petersen
D Petersen Jan 29, 2024 8:45PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
NVO should advance nicely Wednesday on good earnings and a bright 2024 outlook.
Karsten Vester
Karsten Vester Nov 28, 2023 9:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Eli is very keen on disrupting NN but they dont even have cardio vascular studies or a candidate for next generation but NN dos. They are way behind so dont be disrupted by their lobby activities ….
In the Money
In the Money Oct 21, 2023 7:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
140+ eoy
Paul Chan
Paul Chan Oct 21, 2023 7:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Not with the recent deaths from Ozempic.
Karsten Vester
Karsten Vester Oct 21, 2023 7:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Come with dome documentstion dude. Far out to say
dar dar
dar dar Oct 13, 2023 12:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
like all things, eventually we will know the outcome
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email